Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07815197) titled 'Sacituzumab Tirumotecan as Second-Line Treatment for Penile Cancer' on Sept. 2.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Latin American Cooperative Oncology Group
Condition:
Penile Squamous Cell Carcinoma
Metastatic Penile Squamous Cell Carcinoma
Intervention:
Drug: Sacituzumab Tirumotecan
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: January 2027
Target Sample Size: 37
Countries of Recruitment:
Brazil
To know more, visit https://clinical...